Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ella Engels"'
Autor:
David C Klonoff, Stephanie Bassock, Andrea Dwyer, Ella Engels, Marianne Qvist, Thomas Sparre, Soren Snitker
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 6, Pp 978-987 (2021)
Abstract Aims/Introduction A single‐dose, shield‐activated pen‐injector for each of the three approved dose variants (0.25, 0.5 and 1 mg) of once‐weekly subcutaneous semaglutide has been developed to improve usability. This analysis presents
Externí odkaz:
https://doaj.org/article/d86c0cbbc2e047d4b48d1fa903110592
Autor:
Marianne Qvist, Marie Frederiksen, Stephanie Bassock, Thomas Sparre, Søren Snitker, David C. Klonoff, Matthew Marber, Ella Engels
Publikováno v:
Diabetes, Obesity and Metabolism. 23:2590-2594
Subcutaneous semaglutide, at a 2.4 mg once-weekly maintenance dose, is approved in the United States for weight management in individuals with a body mass index (BMI) of 30 kg/m2 or higher, or with a BMI of 27 kg/m2 or higher and at least one obesity
Autor:
Thomas Sparre, Ella Engels, Marianne Qvist, Andrea Dwyer, Stephanie Bassock, Søren Snitker, David C. Klonoff
Publikováno v:
Journal of Diabetes Investigation
Journal of Diabetes Investigation, Vol 12, Iss 6, Pp 978-987 (2021)
Journal of Diabetes Investigation, Vol 12, Iss 6, Pp 978-987 (2021)
Aims/Introduction A single‐dose, shield‐activated pen‐injector for each of the three approved dose variants (0.25, 0.5 and 1 mg) of once‐weekly subcutaneous semaglutide has been developed to improve usability. This analysis presents findings
Autor:
Matthew Marber, Stephanie Bassock, Søren Snitker, Marianne Qvist, Marie Frederiksen, David C. Klonoff, Thomas Sparre, Ella Engels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c0fc74f93118b8d611951b6a8b81bb8
https://doi.org/10.1111/dom.14509/v2/response1
https://doi.org/10.1111/dom.14509/v2/response1